[Articles] Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study

Related Posts

• [Articles] Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study

  Pivekimab sunirine showed single-agent activity across multiple doses, with a recommended phase 2 dose of…

• [Articles] Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

  In this phase 2 study, golidocitinib showed a favourable benefit–risk profile in treating relapsed or…

• Targeting Molecular Alterations in Advanced Solid Tumors: My Pathway Study Phase 2A Study

  KEY TAKEAWAYS MyPathway is a phase IIa multiple basket trial assessing targeted agent activity for…